Dose dependence and time course of the immunologic response to administration of standardized cat allergen extract

Nanda, Anil; O'Connor, Maeve; Anand, Miriam K.; Dreskin, Stephen C.; Zhang, Lening; Hines, Brittany; Lane, Diana R.; Wheat, William H.; Routes, John M.; Sawyer, Richard T.; Rosenwasser, Lanny J.; Nelson, Harold S.

doi:10.1016/j.jaci.2004.08.049

Cited by 130 publications

(115 citation statements)

References 29 publications

(39 reference statements)

Supporting

Mentioning

108

Contrasting

Unclassified

Order By: Relevance

“…Clinical efficacy (reduction of symptoms and/or need for medications) has been confirmed with grass (1102,1104,(1650)(1651)(1652)(1653)(1654)(1655), birch (1650,1651,(1656)(1657)(1658)(1659), ragweed (1660), Russian thistle (1661), Parietaria pollen (1662,1663), mites (1664)(1665)(1666)(1667)(1668)(1669) and cat (1670). It should be noted that three of the studies (1104,1660,1670) clearly demonstrated that the clinical effect is dose dependent. One study showed that recombinant grass pollen vaccines were effective on rhinitis symptoms (1671).…”

Section: Aria: 2008 Updatementioning

confidence: 90%

Allergic Rhinitis and its Impact on Asthma (ARIA) 2008*

Bousquet¹,

Khaltaev²,

Cruz³

et al. 2008

Allergy

3,754

1,761

View full text Add to dashboard Cite

Section: Aria: 2008 Updatementioning

confidence: 90%

Allergic Rhinitis and its Impact on Asthma (ARIA) 2008*

Bousquet¹,

Khaltaev²,

Cruz³

et al. 2008

Allergy

3,754

1,761

View full text Add to dashboard Cite

“…Nevertheless, clinical trials have shown a definite benefit provided subjects are appropriately selected [42]. Clearer evidence of efficacy has been established in animal dander, especially cat allergy [43][44][45][46].…”

Section: Indications For Allergen Immunotherapymentioning

confidence: 99%

Immunotherapy for allergic rhinitis

Walker¹,

Durham

Till

et al. 2011

Clin Experimental Allergy

142

125

View full text Add to dashboard Cite

SummaryAllergic rhinitis (AR) affects more than 20% of the population in the United Kingdom and western Europe and represents a major cause of morbidity that includes interference with usual daily activities and impairment of sleep quality. This guidance prepared by the Standards of Care Committee (SOCC) of the British Society for Allergy and Clinical Immunology (BSACI) is for the management of AR in patients that have failed to achieve adequate relief of symptoms despite treatment with intranasal corticosteroids and/or antihistamines. The guideline is based on evidence and is for use by both adult physicians and paediatricians practising allergy. During the development of these guidelines, all BSACI members were included in the consultation process using a web-based system. Their comments and suggestions were carefully considered by the SOCC. Where evidence was lacking, consensus was reached by the experts on the committee. Included in this guideline are indications and contraindications for immunotherapy, criteria for patient selection, the evidence for short-and long-term efficacy of subcutaneous and sublingual immunotherapy, and discussion on safety and the different modes of immunotherapy including, pre-seasonal and co-seasonal treatments. There are sections on children, allergen standardization, vaccines used in the United Kingdom, oral allergy syndrome, cost effectiveness of immunotherapy and practical considerations of undertaking immunotherapy including recommendations on who should undertake immunotherapy and dosing schedules. Finally, there is discussion on potential biomarkers of response to immunotherapy, the use of component-resolved diagnostics, novel approaches, alternative routes and potential areas for future research.Keywords aeroallergens, allergen, allergic rhinitis, allergen standardization, allergy to animals, allergy to house dust mites, asthma, BSACI, cat allergy, component-resolved diagnostics, cost effectiveness, dosing schedules, grass pollen, guideline, immunotherapy, oral allergy syndrome, perennial rhinitis, pollinosis, ragweed allergy, SAR, seasonal pollen induced rhinitis, subcutaneous immunotherapy, sublingual immunotherapy, tree pollen Submitted 19 February 2011; revised 6 May 2011; accepted 9 May 2011. Executive summaryUntreated rhinitis represents a major cause of morbidity that includes interference with usual daily activities and impaired sleep quality. Immunotherapy, both subcutaneous and sublingual, is an effective treatment for adults and children with severe allergic rhinitis (AR) that does not respond to conventional pharmacotherapy and allergen avoidance measures. The efficacy of immunotherapy depends on correct patient selection, the type of allergen and the product chosen for treatment. Each vaccine requires individual assessment before recommendation for routine use.

show abstract

“…AIT is effective when appropriate doses of allergens are administrated (27). Several studies showed that an optimal maintenance dose needed for AIT through the subcutaneous route is in the range of 5-20 µg of the major allergen found in aeroallergens (28)(29)(30)(31). Therefore, it is quite important to develop a tool for the precise quantitation of allergen components in the allergen extract or the recombinant protein to ensure that it contains an effective therapeutic dose of each of its individual allergen components.…”

Section: Discussionmentioning

confidence: 99%